Epidemiology For The Pharmaceutical
Industry
Louise Watson Consulting works as a limited company in the UK with clients
and contacts worldwide, including faculty.
To provide a comprehensive breadth of service, LWC networks with other freelancers who are experts in their field and who have accumulated a high degree of pharma experience, such as health economists, medical writers, medical scientists, statisticians and programmers.
LWC has experience working in the following therapeutic areas: oncology, pulmonology, allergy, rheumatology, psychiatry, cardiology, and endocrinology. Major clients include a variety of groups within the following companies: GlaxoSmithKline, AstraZeneca, Eli Lilly & Co, Biogen Idec, Actelion, Takeda and Novartis.
Biosketch
Louise Watson-Managing Director Louise has extensive experience in providing
strategic advice to pharma clients in the field of epidemiology. Before
founding LWC, Louise worked in a consultancy company as Head of Epidemiology,
gaining extensive experience in client support for a variety of pharma
clients from epidemiology, health outcomes, safety and marketing groups.
Formerly, Louise worked in the epidemiology department of the global headquarters of GSK. In this role she was responsible for the strategic and business development of global epidemiology programs for respiratory disease, rheumatoid arthritis and allergy across the pipeline, from early development (target to pre-candidate) through to marketed products.
Louise supported diverse groups within the company from Biology and Pharmacology to In-Licencing and Regulatory to optimise epidemiology within the planning process. Louise has also worked as a Clinical Trial Leader within the Clinical Research department of Novartis and has held various research posts in universities in the UK and the Netherlands.
She holds an MSc in the Geography of Health and a Ph.D in Clinical and Respiratory Epidemiology (Groningen University, NL). Louise is also a visiting senior research fellow at Southampton University Primary Care Department where she advises and collaborates on epidemiology and pragmatic prescribing trials.
Louise Watson , Peter Wyld , Daniel Catovsky Disease burden of Chronic Lymphocytic Leukemia within the European Union. In submission to Eur J Haematol
L. Watson, F. Turk, K.F. Rabe. Burden of asthma in the hospital setting. An Australian analysis. Int J Clin Prac 2007; 61 (11): 1884-8
M. Moore P. Little, J Kelly, L. Watson, IG Williamson, K Rumsby, G Warner, and T Fahey. Predicting the duration of symptoms in lower respiratory tract infection (LRTI). British J Gen Prac 2008; 58 (547): 88-92.
L.Watson, F. Turk, P. James, ST Holgate. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med (2007); 101: 1659-1664
L Watson, JM Vonk, CG Löfdahl,
NB Pride, LA Laitinen, JP Schouten, DS Postma
Predictors of COPD symptoms – does the sex of the patient matter? Eur
Respir J. 2006 Aug;28(2):311-8. Epub 2006 May 17
AE Williams , AC Lloyd , L Watson and KF Rabe Cost of scheduled and unscheduled asthma management in seven EU countries. European Respiratory Review. July 2006
L Watson, JM Vonk, CG Löfdahl,
NB Pride, RA Pauwels, LA Laitinen, JP Schouten, DS Postma
Predictors of lung function in subjects with mild to moderate COPD in
association with gender: results from the EUROSCOP study. (Respiratory
Medicine 2006 Apr;100(4):746-53.
R. Gupta, HR Anderson, DP Strachan, WC Maier, L Watson. International trends in admissions and drug sales for asthma. Int J Tuberc Lung Dis. 2006 Feb;10(2):138-45.
P.M Gustafsson, L Watson, KJ Davis, KF Rabe. Poor asthma control in children: evidence from epidemiological surveys and implications for clinical practice. Int J Clin Pract. 2006, March 60, 3, 321-334.
L Watson, HAM Kerstjens, K Rabe, V Kiri, G Visick, DS Postma. Obtaining optimal control in mild asthma: theory and practice. Family Practice 2005 22 (3), 305 - 11
Little P, Rumsby K., Kelly,J.,Watson, L.,
Moore, M., Warner, G., Fahey, T., Williamson, I.
A randomised controlled trial of antibiotic prescribing strategies and
an information leaflet about natural history for acute lower respiratory
tract infection. (JAMA 2005 22, 3029-3035).
Watson L, Vestbo J, Postma DS, Decramer M, Rennard S, Kiri VA, Vermeire PA, Soriano JB. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med. 2004 Dec;98(12):1207-13.
Watson L, Boezen HM, Postma DS. Differences between males and females in the natural history of asthma and COPD. European Respiratory Society Monograph, 2003.
Watson L, Margetts B, Howarth P, Dorward M, Thompson R, Little P. The association between diet and chronic obstructive pulmonary disease in subjects selected from general practice. Eur Respir J, 2002, 20: 313-318
Watson L, Little P, Williamson I, Moore M, Warner G. A validation study of a diary for use in Acute Lower Respiratory Tract Infection. Family Practice. 18;(5), 553-4.
The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J, 2003; 22; 470-477
Little P., Watson L., Morgan S.,
Williamson I. Does prescribing antibiotics prevent rare suppurative
complications of respiratory tract infections?: a data linkage study.
Br J Gen Prac 2002, 52, 187-193
Papers – authored as medical writer
Williams A, Scadding G. Is reliance on self-medication and pharmacy care adequate for rhinitis patients? In submission to Int J Clin Prac
Williams A, Scadding G. Non-compliance with rhinitis medication – does it affect patient outcome? In submission to Int J Clin Prac
Müllerova H, Chigbo C, Hagan G, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. In submission to BMJ.
Victor A Kiri, George T Visick,
Chigbo Chuba, Gerry Hagan, Kourtney J Davis. Incidence of community-acquired
pneumonia (CAP) in patients with chronic obstructive pulmonary disease
(COPD) treated with inhaled corticosteroids. In submission to Thorax.
